Opioids in pain management of blood-related malignancies

Annals of Hematology

Volumn 85, Issue 8, 2006, Pages 489-501

  Niscola, Pasquale ^a   Scaramucci, Laura ^b   Romani, Claudio ^b   Giovannini, Marco ^b   Maurillo, Luca ^a   Poeta, Giovanni ^a   Cartoni, Claudio ^b   Arcuri, Edoardo ^c   Amadori, Sergio ^a   Fabritiis, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Gruppo Italiano di Studio del Dolore in Ematologia (GISDE)   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Haematological malignancies; Morphine mucositis; Opioids; Pain

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BISACODYL; BUPRENORPHINE; BUTYROPHENONE DERIVATIVE; CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DIAMORPHINE; FENTANYL; FENTANYL CITRATE; HALOPERIDOL; HYDROMORPHONE; LAXATIVE; LEVORPHANOL; METHADONE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OPIATE RECEPTOR; OXYCODONE; PARACETAMOL; PETHIDINE; TRAMADOL; UNINDEXED DRUG;

ANALGESIC ACTIVITY; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER PAIN; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CONVULSION; DELIRIUM; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSPHAGIA; DYSPHORIA; EUPHORIA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPERALGESIA; INFECTION; INTESTINE OBSTRUCTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER FAILURE; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; MUCOSA INFLAMMATION; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUTROPENIA; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT CONTROLLED ANALGESIA; PATIENT SATISFACTION; PEPTIC ULCER; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; SEIZURE; SIDE EFFECT; SLOW RELEASE FORMULATION; SOMNOLENCE; SPASTICITY; STOMACH DISEASE; SWEATING; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREMOR; UNSTEADINESS; URINE RETENTION; VOMITING; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; HEMATOLOGIC NEOPLASMS; HUMANS; PAIN;

EID: 33747817395     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0062-4     Document Type: Review

References (115)

1. Niscola P, Arcuri E, Giovannini M et al (2004) Pain syndromes in haematological malignancies: An overview. Hematol J 5(4):293-303
2. Niscola P, Cartoni C, Arcuri E et al (2000) Epidemiologia e fisiopatogenesi del dolore nelle neoplasie ematologiche in fase avanzata. La Rivista Italiana di Cure Palliative (RICP) 2(3):157-161 (Italian)
3. Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S (2003) Pain during bone marrow aspiration: Prevalence and prevention. J Pain Symptom Manage 26(3):860-866 Sep
4. Wolanskyj AP, Schroeder G, Wilson PR, Habermann TM, Inwards DJ, Witzig TE (2000) A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma. Clin Lymphoma 1(2):154-157 Sep
5. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8(1):33-39 Jan
6. Holdsworth MT, Raisch DW, Winter SS et al (2003) Pain and distress from bone marrow aspirations and lumbar punctures. Ann Pharmacother 37(1):17-22 Jan
7. Chordas C (2001) Post-dural puncture headache and other complications after lumbar puncture. J Pediatr Oncol Nurs 18(6):244-259 Nov-Dec
8. Weng HR, Cordella JV, Dougherty PM (2003) Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103(1-2):131-138 May
9. Pederson C, Parran L (1999) Pain and distress in adults and children undergoing peripheral blood stem cell or bone marrow transplant. Oncol Nurs Forum 26(3):575-582 Apr
10. Cella D, Pulliam J, Fuchs H et al (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98(2):406-412 Jul 15
11. Abbas AA, Baker DL, Felimban KS, Husain AH (2004) Musculoskeletal and radiological manifestations of childhood acute leukaemia: A clinical review. Haema 7(4):448-455
12. Aricò M, Boccalatte MFP, Silvestri D et al (2003) Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 88:747-753
13. Niscola P, Scaramucci L, Giovannini M et al (2005) Palliative care in malignant hematology: An overview. Haema 8(2):297-315
14. Giovannini M, Cartoni C, Cedrone M et al (1997) Chemioterapia palliativa in pazienti con neoplasie ematologiche in fase avanzata di malattia: esperienza dell'Unità di Cure domiciliari "Romail" presso l'Istituto d'Ematologia dell'Università "La Sapienza" di Roma. (Abstract). Paper presented at the Eighth Congress of the Società Italiana di Cure Palliative (SICP), Genoa (Italian)
15. No authors listed (1986) World Health Organization. Cancer pain relief. World Health Organization, Geneva
16. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18(4 Suppl):S3-S13 Jul-Aug
17. Kalyuzhny AE (2003) Immunohistochemical localization of mu-, delta- and kappa-opioid receptors within the antinociceptive brainstem circuits. Methods Mol Med 84:79-93
18. Leppert W, Luczak J (2005) The role of tramadol in cancer pain treatment-a review. Support Care Cancer 13(1):5-17 Jan
19. Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43(13):879-923
20. McClellan K, Scott LJ (2003) Tramadol/paracetamol. Drugs 63(11):1079-1086
21. Mercadante S, Arcuri E, Fusco F, Tirelli W, Villari P, Bussolino C, Campa T, De Conno F, Ripamonti C (2005) Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Support Care Cancer 13(9):702-707 Sep
22. Duhmke RM, Cornblath DD, Hollingshead JR (2004) Tramadol for neuropathic pain. Cochrane Database Syst Rev (2):CD003726
23. Boureau F, Legallicier P, Kabir-Ahmadi M (2003) Tramadol in post-herpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Pain 104(1-2):323-331 Jul
24. Cossmann M, Kohnen C, Langford R, McCartney C (1997) Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance. Drugs 53(Suppl 2):50-62
25. No authors listed (2005) Tramadol as an NSAID alternative. Med Lett Drugs Ther 47(1202):13 Feb 14
26. Evans HC, Easthope SE (2003) Transdermal buprenorphine. Drugs 63(19):1999-2010
27. Schriek P (2004) Treatment of cancer-related pain with transdermal buprenorphine: A report of three cases. Support Care Cancer 12(12):882-884 Dec
28. Donnelly S, Davis MP, Walsh D, Naughton M; World Health Organization (2002) Morphine in cancer pain management: A practical guide. Support Care Cancer 10(1):13-35 Jan
29. Wiffen PJ, Edwards JE, Barden J, McQuay HJ (2003) Oral morphine for cancer pain. Cochrane Database Syst Rev (4):CD003868
30. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V; Expert Working Group of the Research Network of the European Association for Palliative Care (2001) Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 84(5):587-593 Mar 2
31. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F (2002) Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 95(1):203-208 Jul 1
32. Harris JT, Suresh Kumar K, Rajagopal MR (2003) Intravenous morphine for rapid control of severe cancer pain. Palliat Med 17(3):248-256 Apr
33. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F (2002) Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 95(1):203-208 Jul 1
34. Moolenaar F, Meijler WJ, Frijlink HW, Visser J, Proost JH (2000) Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain. Eur J Clin Pharmacol 56(3):219-223 Jun
35. Engelhardt T, Crawford M (2001) Sublingual morphine may be a suitable alternative for pain control in children in the postoperative period. Paediatr Anaesth 11(1):81-83 Jan
36. Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS (2002) Intranasal delivery of morphine. J Pharmacol Exp Ther 301(1):391-400 Apr
37. Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A (2005) Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. J Pain Symptom Manage 29(1):80-90 Jan
38. Sear JW (1998) Recent advances and developments in the clinical use of i.v. opioids during the peroperative period. Br J Anaesth 81(1):38-50 Jul
39. Murphy EJ (2005) Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 33(3):311-322 Jun
40. Pillitteri LC, Clark RE (1998) Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis. Bone Marrow Transplant 22(5):495-498 Sep
41. Gossop M, Keaney F, Sharma P, Jacjson M (2005) The unique role of diamorphine in British medical practice: A survey of general practitioners and hospital doctors. Eur Addict Res 11(2):76-82
42. Sarhill N, Walsh D, Nelson KA (2001) Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer 9(2):84-96 Mar
43. Levy MH (2001) Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 5(Suppl A):113-116
44. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16(10):3222-3229 Oct
45. No authors listed (2003) Oral oxycodone: New preparation. No better than oral morphine. Prescr Int 12(65):83-84 Jun
46. Jeal W, Benfield P (1997) Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53(1):109-138 Jan
47. Gourlay GK (2001) Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2(3):165-172 Mar
48. Payne R, Coluzzi P, Hart L et al (2001) Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 22(1):575-583 Jul
49. Mercadante S (1997) Methadone in cancer pain. Eur J Pain 1(2):77-83
50. Bruera E, Palmer JL, Bosnjak S et al (2004) Methadone vs morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 22(1):185-192 Jan 1
51. Mercadante S, Casuccio A, Fulfaro F et al (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 19(11):2898-2904 Jun 1
52. Rowbotham MC, Twilling L, Davies PS et al (2003) Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348(13):1223-1232 Mar 27
53. O'Connor AB, Lang VJ, Quill TE (2005) Eliminating analgesic meperidine use with a supported formulary restriction. Am J Med 118:885-889
54. Seifert CF, Kennedy S (2004) Meperidine is alive and well in the new millennium: Evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy 24(6):776-783 Jun
55. Thompson DR (2001) Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 96(4):1266-1272 Apr
56. Stevens Rom A, Ghazi Salim M (2000) Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control 7(2):132-141
57. Anderson SL, Shreve ST (2004) Continuous subcutaneous infusion of opiates at end-of-life. Ann Pharmacother 38(6):1015-1023 Jun
58. Weinberg DS, Inturrisi CE, Reidenberg B et al (1988) Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44:335-342
59. Burza M, Ginobbi P, Fusco G et al (1998) Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 149(4):277-280 Jul-Aug
60. Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629-2638
61. Brant JM (2001) Opioid equianalgesic conversion: The right dose. Clin J Oncol Nurs 5(4):163-165 Jul-Aug
62. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F (2002) Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 95(1):203-208 Jul 1
63. Citron ML, Johnson-Early A, Boyer M et al (1986) Patient-controlled analgesia for severe cancer pain. Arch Intern Med 146:734-736
64. Ferrell BR, Nash CC, Warfield C (1992) The role of patient-controlled analgesia in the management of cancer pain. J Pain Symptom Manage 7:149-154
65. Hill HF, Chapman CR, Kornell JA et al (1990) Self-administration of morphine in bone marrow transplant patients reduces drug requirement. Pain 40(2):121-129 Feb
66. Dunbar PJ, Buckley P, Gavrin JR, Sanders JE, Chapman CR (1995) Use of patient-controlled analgesia for pain control for children receiving bone marrow transplant. J Pain Symptom Manage 10(8):604-611 Nov
67. Coda BA, O'Sullivan B, Donaldson G, Bohl S, Chapman CR, Shen DD (1997) Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 72(3):333-346 Sep
68. Chapman CR, Donaldson GW, Jacobson RC, Hautman B (1997) Differences among patients in opioid self-administration during bone marrow transplantation. Pain 71(3):213-223 Jul
69. Caraceni A, Cherny N, Fainsinger R et al (2002) Pain measurement tools and methods in clinical research in palliative care: Recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23(3):239-255 Mar
70. Twycross R, Harcourt J, Bergl S (1996) A survey of pain in patients with advanced cancer. J Pain Symptom Manage 12:273-282
71. Davis MP, Walsh D, Lagman R, LeGrand SB (2005) Controversies in pharmacotherapy of pain management. Lancet Oncol 6(9):696-704 Sep
72. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24(6):425-432 Dec
73. Mercadante S, Radbruch L, Caraceni A et al (2002) Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94(3):832-839 Feb 1
74. Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A (2004) Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 27(4):352-359 Apr
75. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V; Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol 19(9):2542-2554 May 1
76. Mercadante S, Arcuri E (2004) Opioids and renal function. J Pain 5(1):2-19 Feb
77. Ballantyne JC, Mao J (2003) Opioid therapy for chronic pain. N Engl J Med 349:1943-1953
78. Staats PS, Markowitz J, Schein J (2004) Incidence of constipation associated with long-acting opioid therapy: A comparative study. South Med J 97(2):129-134 Feb
79. Mercadante S (1999) Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 86(9):1856-1866 Nov 1
80. Mercadante S (2004) Opioid combination for cancer pain. Br J Cancer 90(10):2049 May 17
81. Mach DB, Rogers SD, Sabino MC et al (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113(1):155-166
82. Samad TA, Moore KA, Sapirstein A et al (2001) Interleukin-1 beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410(6827):471-475 Mar 22
83. Ma W, Eisenach JC (2002) Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 15(6):1037-1047 Mar
84. Ito S, Okuda-Ashitaka E, Minami T (2001) Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 41(4):299-332 Dec
85. Banati RB (2002) Brain plasticity and microglia: Is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation? J Physiol Paris 96(3-4):289-299 Apr-Jun
86. Clohisy DR, Mantyh PW (2003) Bone cancer pain. Cancer 97(3 Suppl):866-873 Feb 1
87. Sabino MA, Luger NM, Mach DB, Rogers SD et al (2003) Different tumors in bone each gives rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 104(5):550-558 May 1
88. Berenson JR (2002) Advances in the biology and treatment of myeloma bone disease. Semin Oncol 29(6 Suppl 17):11-16 Dec
89. Pearse RN, Sordillo EM, Yaccoby S et al (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98(20):11581-11586 Sep 25
90. Yaccoby S, Pearse RN, Johnson CL et al (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116(2):278-290 Feb
91. Mercadante S (1997) Malignant bone pain: Pathophysiology and treatment. Pain 69(1-2):1-18 Jan
92. Ripamonti C, Fulfaro F (2000) Malignant bone pain: Pathophysiology and treatments. Curr Rev Pain 4(3):187-196
93. Strupp C, Sudhoff T, Germing U, Hunerliturkoglu A, Schneider P, Niederste-Hollenberg A, Heyll A, Aul C (2000) Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol Rep 7(3):659-661 May-Jun
94. Demarosi F, Lodi G, Soligo D, Sardella A, Volpe AD, Carrassi A, Eliliers GL (2004) Transdermal fentanyl in HSCT patients: An open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant 33(12):1247-1251 Jun
95. Nosari A, Anghilieri M, Cozzi P et al (2002) Transdremal fentanyl is useful in chemotherapy-associated mucositis. Proceedings of the forty-fourth annual meeting of the American Society of Hematology, Pennsylvania: American Society of Hematology. (Abstract) Blood 100, 11(Suppl, part 1):387b
96. Scaramucci L, Bongarzoni V, Niscola P et al (2002) Neuropathy as dominant picture in Primary Amyloidosis: Report of a case with severe clinical course. Proceedings of the seventh annual meeting of the European Haematology Association. Florence (Italy): European Haematology Association. Haematology J 3(Suppl 1):418
97. Ventafridda V, Bianchi M, Ripamonti C et al (1990) Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. Pain 43:155-162
98. Backonja M, Glanzman RL (2003) Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 25(1):81-104 Jan
99. Martin-Kleiner I, Gabrilovac J, Kusec R, Boranic M (2003) Methionine enkephalin suppresses metabolic activity of a leukemic cell line (NALM-1) and enhances CD10 expression. Int Immunopharmacol 3(5):707-711 May
100. Martin-Kleiner I (2002) The effect of opioid agonists of delta-class DSLET, mu-class DAMGO, kappa-class U-69593 and an opioid antagonist, naloxone, on MTT activity of NALM-1 leukemic cells. Biomed Pharmacother 56(9):458-462 Nov
101. Martin-Kleiner I, Gabrilovac J, Boranic M (2004) Opioids as growth regulators of normal and malignant immunohaematopoiesis: A review. Haema 7(3):287-295
102. Sibinga Nes, Goldstein A (1988) Opioid peptides and opioid receptors in cells of the immune system. Ann Rev Immunol 6:219-249
103. Makman MH (1994) Morphine receptor in immunocytes and neurons. Adv Neuroimmunol 4:69-82
104. Machelska H, Stein C (2002) Immune mechanisms in pain control. Anesth Analg 95(4):1002-1008 Oct
105. Brack A, Stein C (2003) The role of the peripheral nervous system in immune cell recruitment. Exp Neurol 184(1):44-49 Nov
106. Machelska H, Stein C (2000) Pain control by immune-derived opioids. Clin Exp Pharmacol Physiol 27(7):533-536 Jul
107. Brack A, Rittner HL, Machelska H et al (2004) Mobilization of opioid-containing polymorphonuclear cells by hematopoietic growth factors and influence on inflammatory pain. Anesthesiology 100(1):149-157 Jan
108. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs: A structure-related activity study. Br J Pharmacol 121:834-840
109. Sacerdote P, Bianchi M, Manfredi B, Panerai AE (1997) Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 72:325-330
110. Mercadante S, Ferrera P, Villari P, Arcuri E (2003) Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage 26(2):769-775
111. Arcuri E (1998) Can tumors act as opioid traps, mimicking opioid tolerance? J Pain Symptom Manage 16(2):78-79 Aug
112. Arcuri E, Ginobbi P, Tirelli W et al (2002) Preliminary in vivo experimental evidence on intratumoral morphine uptake. Possible clinical implications in cancer pain and opioid responsiveness. J Pain Symptom Manage 24(1):1-3 Jul
113. Fimiani C, Arcuri E, Santoni A et al (1999) Mu3 opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release. Cancer Lett 146(1):45-51 Nov 1
114. Furrow BR (2001) Pain management and provider liability: No more excuses. J Law Med Ethics 29:28-51
115. Arcuri E (2002) A project for a hospital without pain. Med Secoli 14(1):233-241